Cover Image
市場調查報告書

NAL Pharmaceuticals Ltd.:產品平台分析

NAL Pharmaceuticals Ltd. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 315711
出版日期 內容資訊 英文 42 Pages
訂單完成後即時交付
價格
Back to Top
NAL Pharmaceuticals Ltd.:產品平台分析 NAL Pharmaceuticals Ltd. - Product Pipeline Review - 2016
出版日期: 2016年03月22日 內容資訊: 英文 42 Pages
簡介

NAL Pharmaceuticals Ltd. ha正在開發新劑型及藥物遞送系統,並應用於該公司的遞送系統。特別是配合中樞神經系統疾病、腫瘤、關節炎和急性疼痛、抽煙、心血管及過敏疾病、呼吸疾病領域的產品。

本報告提供NAL Pharmaceuticals Ltd.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

NAL Pharmaceuticals Ltd.的基本資料

  • NAL Pharmaceuticals Ltd.概要
  • 主要資訊
  • 企業資料

NAL Pharmaceuticals Ltd.:R&D概要

  • 主要的治療範圍

NAL Pharmaceuticals Ltd.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

NAL Pharmaceuticals Ltd.:開發中產品概況

  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式

NAL Pharmaceuticals Ltd.:開發階段不明的開發中產品

  • 開發階段不明的產品/聯合治療模式

NAL Pharmaceuticals Ltd.:藥物簡介

  • pegfilgrastim
  • diclofenac sodium
  • donepezil hydrochloride
  • donepezil hydrochloride Patch
  • formoterol fumarate patch
  • galantamine
  • indomethacin
  • ketoprofen
  • levocetirizine dihydrochloride
  • montelukast sodium
  • NAL-3216
  • NAL-3221
  • NAL-3223
  • nicotine bitartrate
  • rizatriptan benzoate
  • sildenafil citrate
  • sufentanil
  • tadalafil
  • tulobuterol

NAL Pharmaceuticals Ltd.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

NAL Pharmaceuticals Ltd.:暫停中的計劃

NAL Pharmaceuticals Ltd.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07991CDB

Summary

Global Markets Direct's, 'NAL Pharmaceuticals Ltd. - Product Pipeline Review - 2016', provides an overview of the NAL Pharmaceuticals Ltd.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by NAL Pharmaceuticals Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of NAL Pharmaceuticals Ltd.
  • The report provides overview of NAL Pharmaceuticals Ltd. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses NAL Pharmaceuticals Ltd.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features NAL Pharmaceuticals Ltd.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate NAL Pharmaceuticals Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for NAL Pharmaceuticals Ltd.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding NAL Pharmaceuticals Ltd.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • NAL Pharmaceuticals Ltd. Snapshot
    • NAL Pharmaceuticals Ltd. Overview
    • Key Information
    • Key Facts
  • NAL Pharmaceuticals Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • NAL Pharmaceuticals Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • NAL Pharmaceuticals Ltd. - Pipeline Products Glance
    • NAL Pharmaceuticals Ltd. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
    • NAL Pharmaceuticals Ltd. - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • NAL Pharmaceuticals Ltd. - Drug Profiles
    • pegfilgrastim
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • montelukast sodium
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • diclofenac sodium
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • donepezil hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • donepezil hydrochloride Patch
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • formoterol fumarate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • galantamine hydrobromide
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • indomethacin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ketoprofen
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • levocetirizine dihydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NAL-3216
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NAL-3221
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NAL-3223
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • nicotine bitartrate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rizatriptan benzoate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sildenafil citrate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sufentanil citrate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tadalafil
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tulobuterol
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • NAL Pharmaceuticals Ltd. - Pipeline Analysis
  • NAL Pharmaceuticals Ltd. - Pipeline Products by Target
  • NAL Pharmaceuticals Ltd. - Pipeline Products by Route of Administration
  • NAL Pharmaceuticals Ltd. - Pipeline Products by Molecule Type
  • NAL Pharmaceuticals Ltd. - Pipeline Products by Mechanism of Action
  • NAL Pharmaceuticals Ltd. - Dormant Projects
  • NAL Pharmaceuticals Ltd. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • NAL Pharmaceuticals Ltd., Key Information
  • NAL Pharmaceuticals Ltd., Key Facts
  • NAL Pharmaceuticals Ltd. - Pipeline by Indication, 2016
  • NAL Pharmaceuticals Ltd. - Pipeline by Stage of Development, 2016
  • NAL Pharmaceuticals Ltd. - Monotherapy Products in Pipeline, 2016
  • NAL Pharmaceuticals Ltd. - Preclinical, 2016
  • NAL Pharmaceuticals Ltd. - Discovery, 2016
  • NAL Pharmaceuticals Ltd. - Unknown, 2016
  • NAL Pharmaceuticals Ltd. - Pipeline by Target, 2016
  • NAL Pharmaceuticals Ltd. - Pipeline by Route of Administration, 2016
  • NAL Pharmaceuticals Ltd. - Pipeline by Molecule Type, 2016
  • NAL Pharmaceuticals Ltd. - Pipeline Products by Mechanism of Action, 2016
  • NAL Pharmaceuticals Ltd. - Dormant Developmental Projects,2016

List of Figures

  • NAL Pharmaceuticals Ltd. - Pipeline by Top 10 Indication, 2016
  • NAL Pharmaceuticals Ltd. - Pipeline by Stage of Development, 2016
  • NAL Pharmaceuticals Ltd. - Monotherapy Products in Pipeline, 2016
  • NAL Pharmaceuticals Ltd. - Pipeline by Top 10 Target, 2016
  • NAL Pharmaceuticals Ltd. - Pipeline by Top 10 Route of Administration, 2016
  • NAL Pharmaceuticals Ltd. - Pipeline by Molecule Type, 2016
  • NAL Pharmaceuticals Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top